Igamad (Human Anti-D Immunoglobulin)

• Igamad (Human Anti‑D Immunoglobulin) provides passive immunization within the Rh‑D pathway, preventing maternal sensitization to the D antigen.
• Rh‑negative pregnancy: prevents maternal immune sensitization to the D antigen, thereby reducing the risk of hemolytic disease in the fetus and newborn.
• Hemolytic disease of the newborn (HDN): supplies passive anti‑D antibodies that neutralize fetal Rh‑positive red cells, mitigating disease severity and improving neonatal outcomes.
• Immune thrombocytopenic purpura (ITP): used as an adjunct therapy to increase platelet counts by modulating the immune response against platelets.

• Human Anti-D Immunoglobulin consists of purified IgG antibodies that specifically bind the RhD antigen on red blood cells. After intramuscular administration, the antibodies coat any fetal Rh‑positive cells that enter the maternal circulation, masking the D antigen from the maternal immune system. This prevents activation of maternal B‑cells and the subsequent production of endogenous anti‑D antibodies, thereby providing passive immunity and averting sensitization.

Igamad may be associated with a range of adverse reactions following intramuscular injection.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Fever: transient low‑grade temperature elevation.
• Headache: mild headache occurring within hours after administration.
• Nausea: occasional mild nausea or upset stomach.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Hemolysis: rapid destruction of red blood cells leading to anemia.
• Thromboembolic events: rare clot formation that may cause vascular complications.

Prior to using Igamad, several precautionary measures should be observed to ensure patient safety.

• Verify Rh status: confirm that the patient is Rh‑negative before administration.
• Monitor for allergic reactions: observe the patient for signs of hypersensitivity during and after injection.
• Avoid in IgA deficiency: patients with known IgA deficiency may be at increased risk of severe reactions.
• Use cautiously in cardiovascular disease: consider potential volume load and monitor hemodynamics.
• Do not administer intravenously: Igamad is intended for intramuscular use only.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Igamad can interact with certain vaccines and immunomodulatory agents, requiring careful management.

Major Interactions (Avoid)

• Live attenuated vaccines: concurrent use may reduce vaccine efficacy or increase adverse events.
• High‑dose immunoglobulin therapy: may cause immunoglobulin overload and interfere with IgG homeostasis.

Moderate Interactions (Monitor Closely)

• Anticoagulants: monitor coagulation parameters as anti‑D may affect platelet function.
• Corticosteroids: combined immunosuppression may alter response to therapy.
• Other blood products: coordinate timing to avoid additive immunologic effects.